Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:CRSP NASDAQ:OLMA NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$40.970.0%$29.59$16.10▼$41.05$5.24B-0.244.53 million shs549,709 shsCRSPCRISPR Therapeutics$53.57+2.3%$52.41$33.50▼$78.48$5.16B1.741.87 million shs414,969 shsOLMAOlema Pharmaceuticals$15.03+2.7%$16.95$3.89▼$36.26$1.31B2.051.44 million shs69,122 shsXENEXenon Pharmaceuticals$57.89+0.3%$54.09$28.19▼$63.95$5.59B0.651.28 million shs64,743 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%CRSPCRISPR Therapeutics+1.45%+0.61%+5.80%+4.41%+39.23%OLMAOlema Pharmaceuticals+2.23%+0.34%-2.79%-44.42%+163.31%XENEXenon Pharmaceuticals+2.82%+5.84%+1.52%+40.26%+53.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$40.970.0%$29.59$16.10▼$41.05$5.24B-0.244.53 million shs549,709 shsCRSPCRISPR Therapeutics$53.57+2.3%$52.41$33.50▼$78.48$5.16B1.741.87 million shs414,969 shsOLMAOlema Pharmaceuticals$15.03+2.7%$16.95$3.89▼$36.26$1.31B2.051.44 million shs69,122 shsXENEXenon Pharmaceuticals$57.89+0.3%$54.09$28.19▼$63.95$5.59B0.651.28 million shs64,743 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+0.02%-0.05%+1.39%+76.98%+105.06%CRSPCRISPR Therapeutics+1.45%+0.61%+5.80%+4.41%+39.23%OLMAOlema Pharmaceuticals+2.23%+0.34%-2.79%-44.42%+163.31%XENEXenon Pharmaceuticals+2.82%+5.84%+1.52%+40.26%+53.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.04Hold$34.89-14.82% DownsideCRSPCRISPR Therapeutics 2.53Moderate Buy$64.5320.47% UpsideOLMAOlema Pharmaceuticals 2.71Moderate Buy$44.40195.41% UpsideXENEXenon Pharmaceuticals 3.00Buy$73.1326.33% UpsideCurrent Analyst Ratings BreakdownLatest OLMA, XENE, APLS, and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/21/2026OLMAOlema Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026APLSApellis Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$26.00 ➝ $41.004/8/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026APLSApellis Pharmaceuticals Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/2/2026APLSApellis Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $41.004/1/2026APLSApellis Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$37.00 ➝ $41.004/1/2026APLSApellis Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$24.00 ➝ $41.004/1/2026APLSApellis Pharmaceuticals Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold4/1/2026APLSApellis Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$44.00 ➝ $41.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$1.00B5.22$0.21 per share196.04$2.93 per share13.98CRSPCRISPR Therapeutics$3.51M1,471.62N/AN/A$20.17 per share2.66OLMAOlema PharmaceuticalsN/AN/AN/AN/A$5.88 per shareN/AXENEXenon Pharmaceuticals$7.50M745.87N/AN/A$7.53 per share7.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals$22.39M$0.13315.14N/AN/A2.23%8.20%2.38%5/6/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.52N/AN/AN/A-13,856.54%-25.53%-21.66%5/11/2026 (Estimated)OLMAOlema Pharmaceuticals-$162.45M-$1.86N/AN/AN/AN/A-42.95%-38.78%5/12/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.36N/AN/AN/AN/A-55.81%-52.04%5/11/2026 (Estimated)Latest OLMA, XENE, APLS, and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026OLMAOlema Pharmaceuticals-$0.52N/AN/AN/AN/AN/A5/11/2026Q1 2026XENEXenon Pharmaceuticals-$1.17N/AN/AN/A$1.36 millionN/A5/6/2026Q1 2026APLSApellis Pharmaceuticals-$0.38N/AN/AN/A$203.58 millionN/A5/5/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million3/16/2026Q4 2025OLMAOlema Pharmaceuticals-$0.51-$0.50+$0.01-$0.50N/AN/A2/26/2026Q4 2025XENEXenon Pharmaceuticals-$1.20-$1.31-$0.11-$1.31N/AN/A2/24/2026Q4 2025APLSApellis Pharmaceuticals-$0.39$0.47+$0.86-$0.45$199.28 million$199.91 million2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals0.983.142.70CRSPCRISPR TherapeuticsN/A13.3213.32OLMAOlema Pharmaceuticals0.019.959.95XENEXenon PharmaceuticalsN/A13.4113.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%CRSPCRISPR Therapeutics69.20%OLMAOlema Pharmaceuticals91.78%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.80%CRSPCRISPR Therapeutics4.10%OLMAOlema Pharmaceuticals16.36%XENEXenon Pharmaceuticals4.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770128.02 million119.32 millionOptionableCRSPCRISPR Therapeutics46096.43 million92.48 millionOptionableOLMAOlema Pharmaceuticals7087.35 million72.90 millionOptionableXENEXenon Pharmaceuticals21096.64 million92.71 millionOptionableOLMA, XENE, APLS, and CRSP HeadlinesRecent News About These CompaniesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesMay 6 at 3:15 AM | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on MondayMay 4 at 11:48 AM | marketbeat.comXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | financialpost.comFXenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comJennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comPictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENEMay 1, 2026 | marketbeat.comXenon to Report Q1 2026 Financial Results on May 7, 2026April 30, 2026 | globenewswire.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)April 30, 2026 | marketbeat.comXenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton ConferenceApril 26, 2026 | marketbeat.comPeregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENEApril 24, 2026 | marketbeat.comXenon Pharmaceuticals Inc (XENE) Looking At a $2 Billion Opportunity HereApril 23, 2026 | insidermonkey.comXenon's Phase 3 Supports A 'Buy' Despite Its PremiumApril 22, 2026 | seekingalpha.comXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal ...April 19, 2026 | caledonianrecord.comCXenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026April 19, 2026 | quiverquant.comQXenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual MeetingApril 19, 2026 | globenewswire.comXenon Pharmaceuticals Inc.April 19, 2026 | edition.cnn.comXenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)April 16, 2026 | marketbeat.comXenon to Present at Upcoming Investor ConferencesApril 15, 2026 | globenewswire.comXenon Expands 2025 Inducement Equity Incentive PlanApril 13, 2026 | tipranks.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by BrokeragesApril 11, 2026 | marketbeat.comXenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual MeetingApril 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026OLMA, XENE, APLS, and CRSP Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$40.96 -0.01 (-0.01%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$53.57 +1.19 (+2.26%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Olema Pharmaceuticals NASDAQ:OLMA$15.03 +0.39 (+2.66%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Xenon Pharmaceuticals NASDAQ:XENE$57.88 +0.18 (+0.30%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
